TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm” or the “Company”) (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, is pleased to announce that it is implementing an online marketing and awareness program through AGORA Internet Relations Corp. (“AGORACOM”).

AGORACOM’s program will provide the Company a significant level of exposure through millions of content brand insertions on the AGORACOM network and extensive search engine marketing over the next 12 months. In addition, exclusive sponsorships throughdigital properties such as AGORACOM TV, web site and social media channels will be used to significantly raise the brand awareness of the Company among small cap investors.

AGORACOM’s CEO, George Tsiolis, confirms, “We have been tracking CardioComm for the past six years and are very impressed with both the Company’s product releases and changes to fiscal performance. As an FDA cleared, ISO certified and Health Canada/CE approved company, their advances in ECG monitoring and reporting between patients, doctors and hospitals are incredible. This is a story that small cap investors need to know and AGORACOM is excited about the opportunity to tell it for the purposes of expanding CardioComm’s investor awareness far beyond where it is today. We expect to launch the program around November 15th and invite current shareholders to re-engage with the Company on its fully moderated discussion forum at that time.”

Under the agreement, which is subject to TSX Venture Exchange approval, the Company will issue common shares shares of the Company (“Shares”) for services to AGORACOM in exchange for online advertising, marketing and branding services (“Advertising Services”). Pursuant to the terms of the agreement, the Company will be issuing an aggregate of $50,000 worth of Shares, plus HST, for Advertising Services, in $10,000 allotments as follows:

  • Following approval of the agreement by the TSX Venture Exchange, for initial set up, marketing materials and search engine programs;
  • At the completion of each three month period ending February 7, 2019; May 7, 2019; August 7, 2019; and, November 7, 2019.

The number of Shares to be issued at the end of each period will be determined by using the closing price of the Shares on the TSX Venture Exchange on the first trading day following each period for which the Advertising Services were provided by AGORACOM. The term of the agreement is for 12 months effective immediately.

The Company also announced that it issued 187,500 stock options to Etienne Grima, the Company’s CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per share for five years from the date of grant and vest immediately. The grants are subject to the provisions of the Company’s Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites and

download pdf